The global cancer therapeutics market size is expected to reach around US$ 365.99 billion by 2030 from US$ 166.5 billion in 2021 and is expected to grow at an impressive double-digit rate of 9.1% from 2022 to 2030. The global cancer therapeutics market is propelled by numerous factors such asincrease in cancer prevalence,surge in focus of vendors on the emerging markets,rise in cancer research and surge in collaboration between pharmaceutical companies.
The study includes drivers and restraints of this market. The study provides an analysis of the global cancer therapeutics market for the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
Download Free Sample Copy Here (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1546
Why should you invest in this report?
If you are aiming to enter the global cancer therapeutics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for cancer therapeutics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global cancer therapeutics market include:
- F. Hoffmann-La Roche AG
- Bristol-Myers Squibb Company
- AbbVie, Inc.
- Johnson & Johnson
- Celgene Corporation
- AstellasPharma, Inc.
- Pfizer, Inc.
- Novartis AG
- Merck KGaA
- Eli Lilly and Company
Market Segmentation:
By Application
- Blood Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Breast Cancer
- Cervical Cancer
- Head and Neck Cancer
- Glioblastoma
- Malignant Meningioma
- Mesothelioma
- Melanoma
- Others
By Top Selling Drugs
- Revlimid
- Avastin
- Herceptin
- Rituxan
- Opdivo
- Gleevec
- Velcade
- Imbruvica
- Ibrance
- Zytiga
- Alimta
- Xtandi
- Tarceva
- Perjeta
- Temodar
- Others
By End User
- Hospitals
- Specialty Clinics
- Cancer and Radiation Therapy Centers
Regional Analysis:
The geographical analysis of the global cancer therapeutics market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global cancer therapeutics Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global cancer therapeutics market in 2030?
- What is the expected CAGR for the cancer therapeutics market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global cancer therapeutics market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Therapeutics Market
5.1. COVID-19 Landscape: Cancer Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Therapeutics Market, By Top Selling Drugs
8.1. Cancer Therapeutics Market, by Top Selling Drugs Type, 2021-2030
8.1.1. Revlimid
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Avastin
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Herceptin
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Rituxan
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Opdivo
8.1.5.1. Market Revenue and Forecast (2019-2030)
8.1.6. Gleevec
8.1.6.1. Market Revenue and Forecast (2019-2030)
8.1.7. Velcade
8.1.7.1. Market Revenue and Forecast (2019-2030)
8.1.8. Imbruvica
8.1.8.1. Market Revenue and Forecast (2019-2030)
8.1.9. Ibrance
8.1.9.1. Market Revenue and Forecast (2019-2030)
8.1.10. Zytiga
8.1.10.1. Market Revenue and Forecast (2019-2030)
8.1.11. Alimta
8.1.11.1. Market Revenue and Forecast (2019-2030)
8.1.12. Xtandi
8.1.12.1. Market Revenue and Forecast (2019-2030)
8.1.13. Tarceva
8.1.13.1. Market Revenue and Forecast (2019-2030)
8.1.14. Perjeta
8.1.14.1. Market Revenue and Forecast (2019-2030)
8.1.15. Temodar
8.1.15.1. Market Revenue and Forecast (2019-2030)
8.1.16. Others
8.1.16.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Cancer Therapeutics Market, By Application
9.1. Cancer Therapeutics Market, by Application, 2021-2030
9.1.1. Blood Cancer
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Lung Cancer
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Colorectal Cancer
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Prostate Cancer
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Breast Cancer
9.1.5.1. Market Revenue and Forecast (2019-2030)
9.1.6. Cervical Cancer
9.1.6.1. Market Revenue and Forecast (2019-2030)
9.1.7. Head and Neck Cancer
9.1.7.1. Market Revenue and Forecast (2019-2030)
9.1.8. Glioblastoma
9.1.8.1. Market Revenue and Forecast (2019-2030)
9.1.9. Malignant Meningioma
9.1.9.1. Market Revenue and Forecast (2019-2030)
9.1.10. Mesothelioma
9.1.10.1. Market Revenue and Forecast (2019-2030)
9.1.11. Melanoma
9.1.11.1. Market Revenue and Forecast (2019-2030)
9.1.12. Others
9.1.12.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Cancer Therapeutics Market, By End User
10.1. Cancer Therapeutics Market, by End User, 2021-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Cancer and Radiation Therapy Centers
10.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Cancer Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.1.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.3. Market Revenue and Forecast, by End User (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.2.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.6.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.7.3. Market Revenue and Forecast, by End User (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.3.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.6.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.7.3. Market Revenue and Forecast, by End User (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.6.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.7.3. Market Revenue and Forecast, by End User (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.5.3. Market Revenue and Forecast, by End User (2019-2030)
Chapter 12. Company Profiles
12.1. F. Hoffmann-La Roche AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol-Myers Squibb Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. AbbVie, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Johnson & Johnson
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Celgene Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. AstellasPharma, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Novartis AG
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Merck KGaA
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Eli Lilly and Company
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1546
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
0 Comments